Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CHEK NASDAQ:IRIX NASDAQ:NEPH NASDAQ:NXGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHEKCheck-Cap$0.78-0.1%$0.82$0.56▼$3.04$4.56M0.19378,770 shs15,783 shsIRIXIRIDEX$1.01-1.8%$0.99$0.78▼$2.41$16.97M0.5752,317 shs7,785 shsNEPHNephros$3.69-1.7%$3.20$1.36▼$5.00$39.06M1.0918,643 shs17,628 shsNXGLNexGel$2.61-4.6%$2.44$2.00▼$5.10$19.94M0.5970,644 shs4,059 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHEKCheck-Cap-2.65%+6.42%-3.69%+15.63%-60.95%IRIXIRIDEX+3.83%+12.45%+8.99%+9.28%-48.50%NEPHNephros+0.54%-8.09%-3.35%+96.34%+84.73%NXGLNexGel+0.37%+5.00%+20.80%+7.48%+26.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHEKCheck-Cap0.4648 of 5 stars0.05.00.00.00.00.00.6IRIXIRIDEX0.4439 of 5 stars0.04.00.00.00.61.70.0NEPHNephros1.6244 of 5 stars3.53.00.00.00.60.80.0NXGLNexGelN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHEKCheck-Cap 0.00N/AN/AN/AIRIXIRIDEX 0.00N/AN/AN/ANEPHNephros 3.00Buy$5.0035.69% UpsideNXGLNexGel 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHEKCheck-CapN/AN/AN/AN/A$4.05 per shareN/AIRIXIRIDEX$48.80M0.35N/AN/A$0.13 per share7.78NEPHNephros$14.16M2.76$0.02 per share186.40$0.81 per share4.55NXGLNexGel$10.23M1.95N/AN/A$0.90 per share2.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHEKCheck-Cap-$17.57M-$3.00N/A∞N/AN/AN/AN/AN/AIRIXIRIDEX-$8.91M-$0.43N/A∞N/A-14.61%-290.57%-22.86%8/6/2025 (Estimated)NEPHNephros$70K$0.0752.65∞N/A5.16%9.43%7.20%8/6/2025 (Estimated)NXGLNexGel-$3.28M-$0.45N/A∞N/A-30.80%-54.95%-27.84%8/18/2025 (Estimated)Latest CHEK, NXGL, NEPH, and IRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025NEPHNephros-$0.0050$0.0526+$0.0576$0.05$3.67 million$4.88 million5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 million5/13/2025Q1 2025NXGLNexGel-$0.10-$0.09+$0.01-$0.09$2.73 million$2.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHEKCheck-CapN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ANXGLNexGelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHEKCheck-CapN/AN/AN/AIRIXIRIDEX4.281.951.27NEPHNephrosN/A5.924.64NXGLNexGel0.151.881.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHEKCheck-Cap1.07%IRIXIRIDEX20.10%NEPHNephros41.10%NXGLNexGel2.21%Insider OwnershipCompanyInsider OwnershipCHEKCheck-Cap0.48%IRIXIRIDEX7.40%NEPHNephros6.70%NXGLNexGel20.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHEKCheck-Cap805.85 million5.82 millionNot OptionableIRIXIRIDEX12016.79 million15.55 millionOptionableNEPHNephros3010.60 million9.89 millionNot OptionableNXGLNexGel107.66 million6.08 millionNot OptionableCHEK, NXGL, NEPH, and IRIX HeadlinesRecent News About These CompaniesNexGel Inc Stockholders Approve Key Proposals at MeetingJune 20, 2025 | tipranks.comNEXGEL to Participate in the 6th Annual CEO Networking Event Hosted by Semco Capital on June 2ndMay 21, 2025 | finance.yahoo.comEarnings call transcript: Nexgel’s Q1 2025 results show growth, future optimismMay 15, 2025 | uk.investing.comNEXGEL, Inc. (NASDAQ:NXGL) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comNEXGEL, Inc. (NXGL) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comNEXGEL Reports First Quarter 2025 Financial ResultsMay 13, 2025 | taiwannews.com.twT1NXGL : A Peek at NexGel's Future EarningsMay 12, 2025 | benzinga.comNEXGEL to Announce Q1 2025 Financial Results on May 13May 12, 2025 | msn.comNEXGEL, Inc. to Release First Quarter 2025 Financial Results and Host Conference Call on May 13, 2025May 9, 2025 | quiverquant.comQNEXGEL to Report First Quarter 2025 Financial Results on May 13thMay 9, 2025 | globenewswire.comNEXGEL CEO Adam Levy to Present at Planet MicroCap Showcase 2025April 9, 2025 | msn.comNEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24thApril 7, 2025 | markets.businessinsider.comAdam R. Levy Sells 4,000 Shares of NEXGEL, Inc. (NASDAQ:NXGL) StockApril 3, 2025 | insidertrades.comNEXGEL Reports Record-Breaking 2024 Financial PerformanceMarch 27, 2025 | msn.comNEXGEL, Inc. (NASDAQ:NXGL) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | insidermonkey.comEarnings call transcript: Nexgel Q4 2024 sees revenue surge, stock jumpsMarch 26, 2025 | investing.comNEXGEL, Inc. Reports Record Q4 and Full Year 2024 Revenue Growth of 181% and 112% Respectively, Forecasts $13 Million in Revenue for 2025March 26, 2025 | nasdaq.comNEXGEL Reports Record Revenue Growth in 2024March 24, 2025 | tipranks.comNEXGEL targets $13M revenue in 2025 amid product and partnership expansionMarch 24, 2025 | msn.comNEXGEL, Inc. (NXGL) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCHEK, NXGL, NEPH, and IRIX Company DescriptionsCheck-Cap NASDAQ:CHEK$0.78 0.00 (-0.14%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.IRIDEX NASDAQ:IRIX$1.01 -0.02 (-1.84%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Nephros NASDAQ:NEPH$3.68 -0.07 (-1.73%) As of 01:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.NexGel NASDAQ:NXGL$2.60 -0.13 (-4.58%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
